Abbisko Cayman's (HKG:2256) unit Abbisko Therapeutics received clearance for an IND application for ABSK131 from China's National Medical Products Administration, a Thursday filing with the Hong Kong bourse said.
A phase I clinical study of the drug will be conducted in patients with advanced solid tumors. The study population will primarily be made up of patients with methylthioadenosine phosphorylase gene deficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.